Spark Releases Q1 2026 Financial Report: Net Protocol Earnings $3.46 million
BlockBeats News, April 27 - Spark Protocol released its Q1 2026 financial report on April 27. The report shows that the protocol achieved a gross protocol revenue of $31.5 million in the quarter (down 31% QoQ), a net protocol revenue of $6.91 million (down 30% QoQ), and a net protocol surplus of $3.46 million (down 47% QoQ). The protocol's treasury reached a scale of $46.1 million at the end of the quarter (up 5.7% QoQ). Additionally, Spark initiated an SPK token buyback program, investing $0.986 million to repurchase tokens on the open market.
There was a shift in the revenue structure this quarter, with distribution rewards becoming the protocol's largest net revenue contributor ($3.31 million), surpassing for the first time the net revenue from the Spark Liquidity Layer (SLL). The average deployed capital in SLL was $1.93 billion, with an average annual yield of 5.8%. SparkLend continued to support institutional lending business, with its USDT savings pool seeing continuous growth. The Spark institutional lending product deployed $150 million by the end of the quarter, with governance approving a $1 billion cap.
The report noted that the current DeFi lending market's adverse conditions led to a tightening of SLL spreads but significant growth in the protocol's distribution business. USDS, as a scalable savings-based reward mechanism in an unfavorable market environment, is continuously expanding its distribution channels to support multiple chains and various stablecoins.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
UK retail sales unexpectedly increase by 0.5% in August, boosted by warm weather and improved consumer sentiment
Despite rising energy bills, UK retail sales unexpectedly grew in August, as warm weather and improved public sentiment boosted consumption.
Immunology drug development company Electra (ETRA.US) prices IPO at $15, raising $350 millions, to be listed on Nasdaq tonight
Clinical-stage immunology drug development company Electra Therapeutics Inc. raised $350 million in an upsized U.S. initial public offering (IPO), with the offering price set at the midpoint of the marketed range.
Due to yen weakness and government subsidies, Japan has lowered the price of Tesla (TSLA.US) Model Y to below $23,000.
Tesla’s best-selling electric vehicle model is now being sold at the lowest price globally in Tokyo.
Equities: Strong rebound supported by earnings growth – Danske Bank
